Changes in plasma von Willebrand factor and ADAMTS13 levels associated with left atrial remodeling in atrial fibrillation

Thrombosis Research

Volumn 124, Issue 1, 2009, Pages 28-32

  Uemura, Takashi ^a   Kaikita, Koichi ^a   Yamabe, Hiroshige ^a   Soejima, Kenji ^b   Matsukawa, Masakazu ^a   Fuchigami, Shunichiro ^a   Tanaka, Yasuaki ^a   Morihisa, Kenji ^a   Enomoto, Koji ^a   Sumida, Hitoshi ^a   Sugiyama, Seigo ^a   Ogawa, Hisao ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

^b Chemo Sero Therapeutic Research Institute   (Japan)

Author keywords

ADAMTS13; Atrial fibrillation; Left atrial remodeling; VWF

Indexed keywords

ANTIGEN; VON WILLEBRAND FACTOR; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

ADULT; ARTERY DIAMETER; ARTICLE; BLOOD LEVEL; CORRELATION ANALYSIS; DISEASE COURSE; FEMALE; FLOW RATE; HEART ATRIUM APPENDAGE; HEART ATRIUM FIBRILLATION; HEART ATRIUM THROMBOSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; PRIORITY JOURNAL; THROMBOGENESIS;

ADAM PROTEINS; ADULT; AGED; AGED, 80 AND OVER; ATRIAL FIBRILLATION; CASE-CONTROL STUDIES; CHRONIC DISEASE; FEMALE; FOLLOW-UP STUDIES; HEART ATRIA; HUMANS; MALE; MIDDLE AGED; TIME FACTORS; VON WILLEBRAND FACTOR;

EID: 64649105877     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2008.09.012     Document Type: Article

References (38)

1. Benjamin E.J., Wolf P.A., D'Agostino R.B., Silbershatz H., Kannel W.B., and Levy D. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation 98 (1998) 946-952
2. Kannel W.B., Abbott R.D., Savage D.D., and McNamara P.M. Epidemiologic features of chronic atrial fibrillation: the Framingham study. N Engl J Med 306 (1982) 1018-1022
3. Wolf P.A., Dawber T.R., Thomas Jr. H.E., and Kannel W.B. Epidemiologic assessment of chronic atrial fibrillation and risk of stroke: the Framingham study. Neurology 28 (1978) 973-977
4. Kannel W.B., Wolf P.A., Benjamin E.J., and Levy D. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. Am J Cardiol 82 (1998) 2N-9N
5. Kumagai K., Fukunami M., Ohmori M., Kitabatake A., Kamada T., and Hoki N. Increased intracardiovascular clotting in patients with chronic atrial fibrillation. J Am Coll Cardiol 16 (1990) 377-380
6. Li-Saw-Hee F.L., Blann A.D., and Lip G.Y. A cross-sectional and diurnal study of thrombogenesis among patients with chronic atrial fibrillation. J Am Coll Cardiol 35 (2000) 1926-1931
7. Lip G.Y., Lowe G.D., Rumley A., and Dunn F.G. Increased markers of thrombogenesis in chronic atrial fibrillation: effects of warfarin treatment. Br Heart J 73 (1995) 527-533
8. Pongratz G., Brandt-Pohlmann M., Henneke K.H., Pohle C., Zink D., Gehling G., et al. Platelet activation in embolic and preembolic status of patients with nonrheumatic atrial fibrillation. Chest 111 (1997) 929-933
9. Ruggeri Z.M., and Zimmerman T.S. The complex multimeric composition of factor VIII/von Willebrand factor. Blood 57 (1981) 1140-1143
10. Sixma J.J., Sakariassen K.S., Beeser-Visser N.H., Ottenhof-Rovers M., and Bolhuis P.A. Adhesion of platelets to human artery subendothelium: effect of factor VIII-von Willebrand factor of various multimeric composition. Blood 63 (1984) 128-139
11. Sporn L.A., Marder V.J., and Wagner D.D. von Willebrand factor released from Weibel-Palade bodies binds more avidly to extracellular matrix than that secreted constitutively. Blood 69 (1987) 1531-1534
12. Fujikawa K., Suzuki H., McMullen B., and Chung D. Purification of human von Willebrand factor-cleaving protease and its identification as a new member of the metalloproteinase family. Blood 98 (2001) 1662-1666
13. Gerritsen H.E., Robles R., Lammle B., and Furlan M. Partial amino acid sequence of purified von Willebrand factor-cleaving protease. Blood 98 (2001) 1654-1661
14. Soejima K., Mimura N., Hirashima M., Maeda H., Hamamoto T., Nakagaki T., et al. A novel human metalloprotease synthesized in the liver and secreted into the blood: possibly, the von Willebrand factor-cleaving protease?. J Biochem 130 (2001) 475-480
15. Zheng X., Chung D., Takayama T.K., Majerus E.M., Sadler J.E., and Fujikawa K. Structure of von Willebrand factor-cleaving protease (ADAMTS13), a metalloprotease involved in thrombotic thrombocytopenic purpura. J Biol Chem 276 (2001) 41059-41063
16. Furlan M., Robles R., and Lamie B. Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis. Blood 87 (1996) 4223-4234
17. Tsai H.M. Physiologic cleavage of von Willebrand factor by a plasma protease is dependent on its conformation and requires calcium ion. Blood 87 (1996) 4235-4244
18. Mannucci P.M., Canciani M.T., Forza I., Lussana F., Lattuada A., and Rossi E. Changes in health and disease of the metalloprotease that cleaves von Willebrand factor. Blood 98 (2001) 2730-2735
19. Ono T., Mimuro J., Madoiwa S., Soejima K., Kashiwakura Y., Ishiwata A., et al. Severe secondary deficiency of von Willebrand factor-cleaving protease (ADAMTS13) in patients with sepsis-induced disseminated intravascular coagulation: its correlation with development of renal failure. Blood 107 (2006) 528-534
20. Yamazaki S., Taki M., Yasumuro Y., Takayama S., Miyake F., Fujimura Y., et al. [Von Willebrand factor-cleaving protease activity in patients of collagen disease with antiphospholipid antibodies]. Rinsho Byori 50 (2002) 301-307
21. Reiter R.A., Knobl P., Varadi K., and Turecek P.L. Changes in von Willebrand factor-cleaving protease (ADAMTS13) activity after infusion of desmopressin. Blood 101 (2003) 946-948
22. Kaikita K., Soejima K., Matsukawa M., Nakagaki T., and Ogawa H. Reduced von Willebrand factor-cleaving protease (ADAMTS13) activity in acute myocardial infarction. J Thromb Haemost 4 (2006) 2490-2493
23. Matsukawa M., Kaikita K., Soejima K., Fuchigami S., Nakamura Y., Honda T., et al. Serial changes in von Willebrand factor-cleaving protease (ADAMTS13) and prognosis after acute myocardial infarction. Am J Cardiol 100 (2007) 758-763
24. Fuchigami S., Kaikita K., Soejima K., Matsukawa M., Honda T., Tsujita K., et al. Changes in plasma Von Willebrand factor-cleaving protease (ADAMTS13) levels in patients with unstable angina. Thromb Res 122 (2008) 618-623
25. Gustafsson C., Blomback M., Britton M., Hamsten A., and Svensson J. Coagulation factors and the increased risk of stroke in nonvalvular atrial fibrillation. Stroke 21 (1990) 47-51
26. Soejima K., Nakamura H., Hirashima M., Morikawa W., Nozaki C., and Nakagaki T. Analysis on the molecular species and concentration of circulating ADAMTS13 in Blood. J Biochem 139 (2006) 147-154
27. Conway D.S., Pearce L.A., Chin B.S., Hart R.G., and Lip G.Y. Plasma von Willebrand factor and soluble p-selectin as indices of endothelial damage and platelet activation in 1321 patients with nonvalvular atrial fibrillation: relationship to stroke risk factors. Circulation 106 (2002) 1962-1967
28. Fukuchi M., Watanabe J., Kumagai K., Katori Y., Baba S., Fukuda K., et al. Increased von Willebrand factor in the endocardium as a local predisposing factor for thrombogenesis in overloaded human atrial appendage. J Am Coll Cardiol 37 (2001) 1436-1442
29. Heppell R.M., Berkin K.E., McLenachan J.M., and Davies J.A. Haemostatic and haemodynamic abnormalities associated with left atrial thrombosis in non-rheumatic atrial fibrillation. Heart 77 (1997) 407-411
30. Bongers T.N., de Maat M.P., van Goor M.L., Bhagwanbali V., van Vliet H.H., Gomez Garcia E.B., et al. High von Willebrand factor levels increase the risk of first ischemic stroke: influence of ADAMTS13, inflammation, and genetic variability. Stroke 37 (2006) 2672-2677
31. Bernardo A., Ball C., Nolasco L., Moake J.F., and Dong J.F. Effects of inflammatory cytokines on the release and cleavage of the endothelial cell-derived ultralarge von Willebrand factor multimers under flow. Blood 104 (2004) 100-106
32. Conway D.S., Buggins P., Hughes E., and Lip G.Y. Relationship of interleukin-6 and C-reactive protein to the prothrombotic state in chronic atrial fibrillation. J Am Coll Cardiol 43 (2004) 2075-2082
33. Psychari S.N., Apostolou T.S., Sinos L., Hamodraka E., Liakos G., and Kremastinos D.T. Relation of elevated C-reactive protein and interleukin-6 levels to left atrial size and duration of episodes in patients with atrial fibrillation. Am J Cardiol 95 (2005) 764-767
34. Fatkin D., Kelly R.P., and Feneley M.P. Relations between left atrial appendage blood flow velocity, spontaneous echocardiographic contrast and thromboembolic risk in vivo. J Am Coll Cardiol 23 (1994) 961-969
35. Handke M., Harloff A., Hetzel A., Olschewski M., Bode C., and Geibel A. Left atrial appendage flow velocity as a quantitative surrogate parameter for thromboembolic risk: determinants and relationship to spontaneous echocontrast and thrombus formation-a transesophageal echocardiographic study in 500 patients with cerebral ischemia. J Am Soc Echocardiogr 18 (2005) 1366-1372
36. Mondillo S., Sabatini L., Agricola E., Ammaturo T., Guerrini F., Barbati R., et al. Correlation between left atrial size, prothrombotic state and markers of endothelial dysfunction in patients with lone chronic nonrheumatic atrial fibrillation. Int J Cardiol 75 (2000) 227-232
37. Matsumoto M., Kawaguchi S., Ishizashi H., Yagi H., Iida J., Sakaki T., et al. Platelets treated with ticlopidine are less reactive to unusually large von Willebrand factor multimers than are those treated with aspirin under high shear stress. Pathophysiol Haemost Thromb 34 (2005) 35-40
38. Li-Saw-Hee F.L., Blann A.D., and Lip G.Y. Effects of fixed low-dose warfarin, aspirin-warfarin combination therapy, and dose-adjusted warfarin on thrombogenesis in chronic atrial fibrillation. Stroke 31 (2000) 828-833